CURRENT
ISSUE
1584
November 4, 2019

Diet, exercise, and weight loss can improve glycemic control, but almost all patients with type 2 diabetes eventually require drug therapy. Treating to a glycated hemoglobin (A1C) concentration of <7% can prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular complications and death is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease (CVD), a history of severe hypoglycemia, diabetes-related complications, a limited life expectancy, or a long duration of disease.Continue reading

More from Issue 1584
Previous Issue: 1583      October 21, 2019
Coming Soon
Turmeric Supplements
Upadacitinib (Rinvoq) - A New JAK Inhibitor for Rheumatoid Arthritis
Cannabis and Cannabinoids
Pitolisant (Wakix) for Excessive Daytime Sleepiness
Drugs for Some Common Eye Disorders
Search
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
 Tweets
Advance Release
ADVANCE
RELEASE

The FDA has approved a new formulation of glucagon (Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products (Glucagon Emergency Kit, and others), Gvoke does not require reconstitution before administration. A glucagon nasal ... Continue reading